FILE PHOTO: The exterior of the European Medicines Agency is seen in Amsterdam, Netherlands, December 18, 2020. REUTERS/Piroschka van de Wouw/File Photo
(Reuters) – The European medicines regulator said on Monday it would hold a meeting this week on the information gathered into whether the AstraZeneca COVID-19 vaccine contributed to thromboembolic events in those inoculated.
While its investigation is ongoing, the European Medicines Agency remains of the view that the benefits of the AstraZeneca vaccine in preventing COVID-19 outweigh the risks of side effects. (bit.ly/3trmufB)
Reporting by Yadarisa Shabong in Bengaluru; Editing by Shounak Dasgupta
Our Standards: The Thomson Reuters Trust Principles.
The UK economy contracted again in late 2025, with weaker services output fuelling expectations of…
U.S. lawmakers are raising alarms over Nvidia’s AI chip exports to China, warning that allowing…
The historic occasion recognized and immortalized Adesina’s name, leadership, contributions to Africa, and his visionary…
Record 215,700 annual sales worth AED 686.8 billion underscore city's position as a premier global…
The British Safety Council has officially opened applications for the International Safety Awards (ISA) 2026,…
Rising food prices are reshaping dining habits in the U.S., giving rise to the “Appetizer…